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Abstract
An improved synthesis of the antiviral drug adefovir is presented. Problems associated with current routes to adefovir include capri-
cious yields and a reliance on problematic reagents and solvents, such as magnesium tert-butoxide and DMF, to achieve high
conversions to the target. A systematic study within our laboratory led to the identification of an iodide reagent which affords
higher yields than previous approaches and allows for reactions to be conducted up to 10 g in scale under milder conditions. The
use of a novel tetrabutylammonium salt of adenine facilitates alkylations in solvents other than DMF. Additionally, we have investi-
gated how regioselectivity is affected by the substitution pattern of the nucleobase. Finally, this chemistry was successfully applied
to the synthesis of several new adefovir analogues, highlighting the versatility of our approach.
Introduction
The acyclic nucleoside phosphonate adefovir (1) [1], adminis-
tered as its dipivoxil prodrug form (2) [2], is used clinically for
the treatment of infections caused by the hepatitis B virus
(HBV) [3-5] and the herpes simplex virus (HSV, Figure 1)
[5,6]. While 1 possesses inhibitory activity against the human
immunodeficiency virus (HIV) [1,5], it has not been approved
by the FDA for the treatment of HIV as the dose required to
elicit inhibition can cause nephrotoxicity [7].
The mode of action of adefovir has been widely studied and
involves the inhibition of viral replication by the termination of
DNA synthesis [8-10]. Although adefovir was described in
Figure 1: Adefovir (1) and its prodrug 2.
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Scheme 1: Literature syntheses of 1.
1986 for the first time by Holý, De Clercq and co-workers, it is
still actively employed in research today [11-13]. Adefovir is
often used as a benchmark against which the relative activity of
other antiretroviral drugs is measured [14-17]. In addition, the
development of new prodrugs of current antiretrovirals remains
an important field of study [18]. The efficacy of investigational
prodrug strategies is typically measured by derivatising proven
therapeutics such as adefovir and comparing the properties of
the resulting compounds to the parent substrate [15,19-30]. Ad-
ditionally, the solid state and spectroscopic properties of
adefovir have been the subject of several recent studies [31-34].
It is clear, therefore, that there is still demand for a robust syn-
thetic route to adefovir. The most widely employed method for
accessing adefovir is shown in Scheme 1 [17,35,36]. Alkyl-
ation of commercially available adenine (3) to form alcohol 4
and further base-mediated alkylation with tosylate 5 affords
phosphonate ester intermediate 6. Subsequent dealkylation of 6
using trimethylsilyl bromide (TMSBr) gives adefovir (1). The
related analogue tenofovir, developed as an anti-HIV agent,
may be prepared in a similar manner [37,38].
The poor solubility of adenine and its derivatives in most
organic solvents restricts the choice of solvent for this and
subsequent reactions to polar aprotic solvents such as DMF,
NMP and DMSO [38].
The choice of base for the alkylation of alcohol 4 with tosylate
5 has been the subject of recent studies [35,37-39]. While it was
demonstrated that magnesium tert-butoxide (MTB) is the
optimum base for this transformation (Scheme 1), it is not with-
out drawbacks. MTB is expensive and hydrolyses on storage
when exposed to moisture. The yield for the reaction is often
inconsistent, being highly dependent on the quality of the MTB
employed. The reaction does not proceed to completion when a
stoichiometric amount of the base is used and up to 3.0 equiva-
lents may be required in order to ensure complete consumption
of the starting alcohol. The resultant magnesium salts are highly
deliquescent and form a sticky resin on exposure to atmos-
pheric moisture. This resin hinders the isolation of phosphonate
6 and stymies scale-up. Finally, several byproducts, including
the ethyl ether of 4 and the hemi-dealkylated ester of 6, are pro-
duced during this reaction, further reducing the atom economy
of this approach [35,38]. In an attempt to overcome these diffi-
culties, some groups have explored telescoping the MTB-medi-
ated alkylation of 4 with the subsequent dealkylation of 6
[38,40]. However, as trimethylsilyl bromide (TMSBr) is mois-
ture sensitive, telescoping the two reactions is difficult due to
the hygroscopic nature of both the polar aprotic solvents em-
ployed and MTB itself. An improved synthetic route to adefovir
(1), which avoids at least some of these difficulties and espe-
cially the use of MTB, would be highly desirable.
Results and Discussion
We initially investigated the use of phosphonate reagents bear-
ing alternative leaving groups in an effort to improve the in situ
conversion from 4 to 6, thereby improving the yield of this reac-
tion. We selected iodide 7 and triflate 8 for this study and com-
pared the conversion of 4 to 6 by 1H NMR (Table 1, entries
1–3). Unfortunately, we found that tosylate 5 remained the su-
perior alkylating agent under these conditions. The reaction of 4
with iodide 7 afforded only a trace amount of the phosphonate,
with mostly unreacted starting material evident in the 1H and
31P NMR spectra of the crude reaction mixture. The reaction
Beilstein J. Org. Chem. 2019, 15, 801–810.
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Table 1: Impact of the leaving group on in situ conversion of 4 to 6.
Entry Electrophilea Leaving group (X) Conversionb Yieldc
1 5 OTs 85% 43%
2 7 I 56% 24%
3 8 OTf trace –
aReactions were carried out on a 3 mmol scale, 0.1 M concentration using 1.50 equiv of the electrophile. bMeasured by analysis of the 1H NMR spec-
trum of the crude reaction mixture after removal of the solvent in vacuo, comparing the NCH2 signals of 4 and 6 at 4.19 ppm and 4.33 ppm, respec-
tively. cYield following purification by column chromatography.
Figure 2: Retrosynthetic analysis of 6 to synthons 9 and 10.
with triflate 8 resulted in a significantly lower conversion to 6
than when tosylate 5 was employed. Optimisation of other
aspects of this reaction (e.g., choice of base, solvent, tempera-
ture and the role of additives) has already been investigated by
Brown Ripin [37,40] and Riley [38] which suggested that
further investigation had limited potential.
Given the issues encountered in employing MTB, we next in-
vestigated the introduction of the phosphonate ester as the
nucleophile rather than as the electrophile (Figure 2).
Commercially available alcohol 10 was prepared by adapting a
previously reported literature procedure where diethyl phos-
phonate (11) was condensed with paraformaldehyde in the pres-
ence of catalytic triethylamine (Scheme 2) [41]. Iodide 9 was
accessed in two steps from adenine (3). The highly regioselec-
tive alkylation of adenine (3) with an excess (4.0 equiv) of 1,2-
dibromoethane furnished bromide 12 in 78% yield. Despite the
poor solubility of 12 in acetonitrile, the compound was success-
fully converted to iodide 9 via a Finkelstein reaction. Unfortu-
nately, subsequent alkylation of 10 with iodide 9 in the pres-
ence of sodium hydride furnished 6 in a poor yield of 21%. For-
mation of self-alkylation product 13 constituted the major reac-
tion pathway when the reaction was stirred for prolonged
periods of time or heated to higher temperatures. Consequently,
the overall yield of this process, at 14%, is lower than that of
the process outlined in Scheme 1.
Given the ease of alkylation of 3 with 1,2-dibromoethane, we
wondered if alkylation of adenine with advanced intermediate
14 might represent a facile route to 6 (Figure 3).
Holý and co-workers have previously utilised a similar alkyl
chloride reagent to access adefovir analogues, but found that
recourse to an isopropyl ester intermediate was necessary as the
corresponding ethyl ester was prone to unwanted dealkylation
under their harsh reaction conditions [13]. We reasoned that
iodide 14 would facilitate alkylation under much milder condi-
tions, and that the ethyl esters would, therefore, remain intact.
Other comparable alkylating agents have also been employed in
the synthesis of acyclic nucleoside phosphonates including
mesylates [42], tosylates [16,43,44] and alkyl chlorides [45-51].
Alkylation reactions conducted with these electrophiles general-
ly require higher temperatures. Furthermore, these reagents typ-
Beilstein J. Org. Chem. 2019, 15, 801–810.
804
Scheme 2: Forward synthesis of 6 from 9 and 10.
Figure 3: Retrosynthesis of 6 to synthons 14 and 3.
Scheme 3: Application of related alkyl iodide 15 [52].
ically afford products in low to moderate yields as the reactions
fail to reach completion or else furnish multiple side-products.
The successful application of such iodide-based electrophiles is
precedented, as demonstrated by the work of Ubasawa et al. in
their preparation of purine analogue 17 from 15 (Scheme 3)
[52]. A similar approach is outlined in a 1998 patent by the
same group [53].
Iodide 14 was prepared over two steps from commercially
available 2-chloroethyl chloromethyl ether (18, Scheme 4).
Firstly, 18 was subjected to an Arbuzov rearrangement to
furnish phosphonate 19 in quantitative yield. A subsequent
Finkelstein reaction afforded iodide 14. During the optimisa-
tion of this transformation, we observed that 2.0 equivalents of
sodium iodide were required in order to achieve complete
consumption of 19. Iodide 14 was stored under a nitrogen atmo-
sphere over copper wire in an amber container and found to be
stable for over one year. Gratifyingly, alkylation of adenine
with iodide 14 proceeded smoothly under mild conditions to
furnish phosphonate 6 in 70% yield. The overall yield of 6 from
18 was 58% which compared very favourably with that re-
ported in Scheme 1. Interestingly, the unnatural N7-regio-
isomer 20 was also isolated in 16% yield, which was readily
separable from 6 by column chromatography. The synthesis of
20 has been reported only once before and the resulting phos-
phonic acid also possesses antiviral activity [54]. The authors
report that 20 was prepared in four steps while our three step
route affords 20 in a comparable overall yield of 13%.
Beilstein J. Org. Chem. 2019, 15, 801–810.
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Scheme 4: Synthesis of 6 and 20 via iodide 14.
Table 2: Impact of base, solvent and temperature on reaction performance and regioselectivity.
Entry Base Solvent Temperature (°C) N9:N7a Conversionb
1 NaOH DMF rt 3:1 100%
2 KOH DMF rt 3:1 100%
3 NEt3 DMF rt –c trace
4 DBU DMF rt 4:1d 33%
5 DMAP DMF rt –c N.P.
6 Cs2CO3 DMF rt 4:1 100%
7 K2CO3 DMF rt 4:1 100%
8 K2CO3 NMP rt 4:1 100%
9 K2CO3 DMF 0 4:1 100%
10 K2CO3 DMF 50 4:1 100%
11 K2CO3 water:DMF (30% v/v) rt 4:1 59%
12 K2CO3 MeCN rt –c N.P.
We conducted a temperature, solvent and base screen to deter-
mine what impact these parameters have on the regioselectivity
of the alkylation (Table 2). The overall regioselectivity
appeared insensitive to the reaction conditions with only a slight
decrease in selectivity for 6 observed when hydroxylic bases
were employed in the reaction (Table 2, entries 1 and 2). Tem-
perature was observed to have no effect on the regioselectivity
(Table 2, entries 7, 9 and 10). Similarly, no improvement was
observed when other aprotic solvents were used in place of
DMF (Table 2, entries 8, 12, 13, 15 and 16). The same regiose-
Beilstein J. Org. Chem. 2019, 15, 801–810.
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Table 2: Impact of base, solvent and temperature on reaction performance and regioselectivity. (continued)
13 DBU MeCN rt –c N.P.
14 NaH DMF rt 4:1 100%
15 K2CO3 EtOAc rt –c N.P.
16 K2CO3 acetone rt –c N.P.
17 K2CO3 EtOH rt –e trace
18 K2CO3 cyrene rt –c N.P.
aDetermined by integration of the NCH2 signals from 6 and 20 at 4.33 ppm and 4.50 ppm, respectively, in the 1H NMR spectra of the crude reaction
mixture after removal of the solvent in vacuo. bDetermined by integration of the C(8)H in 3, 6 and 20 in the 1H NMR spectra of the crude reaction mix-
ture. cNo reaction observed, only starting material evident in the 1H NMR spectra of the crude reaction mixtures. dReaction did not reach completion.
eDegradation of iodide 14 evident in 1H NMR and 31P NMR spectra of crude reaction mixture. Only traces of product formed. N.P. = no product
formed.
Scheme 5: Synthesis of phosphonate 6 using novel salt 21.
lectivity was observed when the reaction was performed in
either NMP or DMF, even though adenine (3) was more soluble
in NMP. No reaction was observed in acetonitrile, acetone or
ethyl acetate, presumably due to the insolubility of adenine (3)
at room temperature. When wet DMF was employed (Table 2,
entry 11), no change in the regioselectivity occurred, although
the reaction was found to proceed more slowly, having not
reached completion after 30 hours. Conducting the reaction in
ethanol (Table 2, entry 17) resulted in degradation of the iodide
starting material and the formation of only trace amounts of
product. No reaction was observed in cyrene (Table 2, entry
18), often employed as a green alternative to DMF [55].
In a bid to replace DMF as the solvent, we turned our attention
to more soluble adenine analogues and investigated the forma-
tion of 21, a novel tetrabutylammonium salt of adenine
(Scheme 5). Preparation of 21 was facile and the salt was isolat-
ed quantitatively as a colourless powder following work-up.
Gratifyingly, the subsequent alkylation with iodide 14 in aceto-
nitrile proceeded in comparable yields to those in DMF, consti-
tuting an attractive alternative to current literature methods for
accessing 6.
To explore the utility of iodide 14 in the synthesis of novel
antivirals, we examined its reactivity towards other 6-substi-
tuted purine nucleobase analogues (Scheme 6). Alkylation of
both 6-chloropurine (22) and N6-benzyladenine (25) afforded
the corresponding N9-regioisomers as the major product as de-
termined by 1H NMR spectroscopy (Scheme 6a,b). The major
isomers were then isolated and subsequently converted to phos-
phonate 6 in order to confirm the degree of regioselectivity.
Interestingly, the amidine moiety in 28 favoured alkylation at
N7 and 29 was isolated in 79% yield following purification by
column chromatography (Scheme 6c).
Pal and co-workers previously reported the N7-selective alkyl-
ation of 28 using other electrophiles [56]. They confirmed that
the reaction had occurred at N7 via HMBC analysis and the
identification of a correlation between the methylene protons
adjacent to the purine ring with C-5. A similar analysis by us
revealed the same correlation, confirming 29 as the major prod-
uct (Figure 4). While the amidine is itself an important moiety
in medicinal chemistry [57], it can also be readily converted to
other functional groups including nitrogen-containing hetero-
cycles [58]. Consequently, the use of the amidine moiety to
direct the N7-selective alkylation with iodide 14 may likewise
facilitate the preparation of other N7-functionalised adefovir an-
alogues for evaluation.
Finally, we investigated whether a similar strategy could be
exploited to access adefovir dipivoxil (2) directly. Although we
were able to successfully prepare novel phosphonate 33 via
phosphonic acid 31, subsequent attempts at converting 33 to the
corresponding iodide 34, or alkylation of salt 21 were unsuc-
cessful and hence we were unable to access 2 (Scheme 7).
Instead, the major product isolated in both cases was novel
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Scheme 6: Application of iodide 14 in the synthesis of adefovir analogues.
Figure 4: HMBC spectrum confirms N7-selectivity for the major product 29.
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Scheme 7: Attempted synthesis of adefovir dipivoxil (2) exploiting phosphonate 33.
heterocycle 35. It is likely that cleavage of one of the pival-
oxymethyl groups, followed by intramolecular cyclisation,
results in the formation of 35. Microwave heating of 33 in the
presence of DBU also furnishes cyclic phosphonate 35 in excel-
lent yields.
Conclusion
We have described a synthetic route to phosphonate intermedi-
ate 6 which has a number of distinct advantages when com-
pared to previous approaches. While the standard approach to
adefovir relies heavily on the use of magnesium tert-butoxide,
an expensive, troublesome and capricious reagent, our im-
proved synthesis of adefovir avoids this. As adenine is intro-
duced later in our synthetic sequence, fewer steps are carried
out in hazardous, environmentally harmful solvents such as
DMF or NMP. Furthermore, the introduction of a more reactive
electrophile in 14 means that the critical alkylation step is con-
ducted at room temperature. Additionally, the preparation of
chloride 19 is a solventless reaction and the subsequent conver-
sion of 19 to iodide 14 takes place in acetone, a green solvent.
Our route also produces fewer byproducts and is higher yielding
than the standard synthesis of adefovir, making it a highly
attractive alternative for those interested in the study of this
molecule and its analogues, particularly on a laboratory scale.
In addition, through the use of salt 21, the preparation of 6
can be achieved without the use of DMF as a solvent. Further-
more, this approach gives synthetically useful quantities of
N7-substituted analogue 20, via a more concise route than the
current literature procedure. The preparation of a number of
novel adefovir analogues using iodide 14 highlights the utility
of this reagent. Finally, strategic incorporation of an amidine
moiety allows for regioselective alkylations with 14 and
facilitates the synthesis of novel N7-substituted adefovir ana-
logues.
Supporting Information
Supporting Information File 1
Experimental part and NMR spectra.
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